NEW HAVEN, Conn. and MONMOUTH JUNCTION, N.J. and LOS ANGELES, July 5, 2023 /PRNewswire/ — DiamiR Biosciences, a developer of innovative non-invasive blood-based diagnostic tests for brain health and other diseases, today announced that it has entered into an agreement with JADBio to utilize its Automated Machine Learning (AutoML) Platform and Services for development of … Continued
NEW HAVEN, Conn. and MONMOUTH JUNCTION, N.J., June 28, 2023 /PRNewswire/ — DiamiR Biosciences, a developer of innovative non-invasive blood-based diagnostic tests for brain health and other diseases, today announced that the data related to analytical validation of the company’s 24 microRNA panel for risk assessment of Alzheimer’s disease, CogniMIR®, has been published in the journal Diagnostics. Titled “Analytical Validation … Continued
NEW HAVEN, Conn.and MONMOUTH JUNCTION, N.J., June 20, 2023 /PRNewswire/ — DiamiR Biosciences, a developer of innovative non-invasive blood-based diagnostic tests for brain health and other diseases, today announced that it will present two posters at the Alzheimer’s Association International Conference (AAIC), taking place July 16 – 20, 2023, in Amsterdam, Netherlands, and online.
NEW HAVEN, Conn. and MONMOUTH JUNCTION, N.J., Nov. 28, 2022 /PRNewswire/ — DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced that it will present a poster at the 15th Clinical Trials on Alzheimer’s Disease (CTAD), taking place November 29 – December 2, 2022, at the Hilton Union … Continued
NEW HAVEN, Conn. and MONMOUTH JUNCTION, N.J., Nov. 7, 2022 /PRNewswire/ — DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced that the company’s management will participate in the BioFuture Conference being held on November 7-9, 2022 at the Lotte New York Palace in New York City, NY. … Continued
NEW HAVEN, Conn. and MONMOUTH JUNCTION, N.J., Aug. 30, 2022 /PRNewswire/ – DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the expansion of its management team by the appointment of Fred Knechtel as Chief Financial Officer (CFO), effective immediately. “We are excited to welcome Fred to DiamiR … Continued
NEW HAVEN, Conn. and MONMOUTH JUNCTION, N.J., July 11, 2022 /PRNewswire/ — DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the appointment of Alidad Mireskandari, Ph.D., MBA as Chief Executive Officer (CEO), effective immediately. Dr. Mireskandari has over 12 years of life sciences industry experience with a focus on molecular … Continued
MONMOUTH JUNCTION, N.J., March 17, 2021 /PRNewswire/ — DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced that it has entered into a definitive agreement to acquire a CLIA (Clinical Laboratory Improvement Amendments) certified laboratory in New Haven, CT from Interpace Biosciences, Inc. Subject to specific terms and … Continued
MONMOUTH JUNCTION, N.J., Feb. 11, 2021 /PRNewswire/ — DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced that it has received a notice of allowance from the United States Patent & Trademark Office (USPTO) for U.S. Patent Application No. 16/028,206 entitled “Methods of using miRNA from bodily fluids … Continued
MONMOUTH JUNCTION, N.J., Oct. 5, 2020 /PRNewswire/ — DiamiR, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, today announced that Dr. Kira Sheinerman, Chief Executive Officer, will be presenting and participating in a panel discussion at The 21st International Conference on Alzheimer’s Drug Discovery hosted by the Alzheimer’s Drug Discovery Foundation (ADDF) and held virtually October … Continued
